- Home
- CRMD vs PCRX Comparison
CRMD vs PCRX Comparison
Compare CRMD & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- PCRX
- Stock Information
- Founded
- CRMD 2006
- PCRX 2006
- Country
- CRMD United States
- PCRX United States
- Employees
- CRMD N/A
- PCRX N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CRMD Health Care
- PCRX Health Care
- Exchange
- CRMD Nasdaq
- PCRX Nasdaq
- Market Cap
- CRMD 626.8M
- PCRX 604.7M
- IPO Year
- CRMD 2010
- PCRX 2011
- Fundamental
- Price
- CRMD $10.33
- PCRX $17.38
- Analyst Decision
- CRMD Strong Buy
- PCRX Buy
- Analyst Count
- CRMD 5
- PCRX 10
- Target Price
- CRMD $15.20
- PCRX $26.60
- AVG Volume (30 Days)
- CRMD 1.6M
- PCRX 547.0K
- Earning Date
- CRMD 10-30-2024
- PCRX 11-06-2024
- Dividend Yield
- CRMD N/A
- PCRX N/A
- EPS Growth
- CRMD N/A
- PCRX N/A
- EPS
- CRMD N/A
- PCRX N/A
- Revenue
- CRMD $12,262,234.00
- PCRX $694,957,000.00
- Revenue This Year
- CRMD N/A
- PCRX $4.59
- Revenue Next Year
- CRMD $277.75
- PCRX N/A
- P/E Ratio
- CRMD N/A
- PCRX N/A
- Revenue Growth
- CRMD 41184.20
- PCRX 4.40
- 52 Week Low
- CRMD $2.89
- PCRX $11.16
- 52 Week High
- CRMD $13.85
- PCRX $35.95
- Technical
- Relative Strength Index (RSI)
- CRMD 47.20
- PCRX 58.45
- Support Level
- CRMD $10.16
- PCRX $16.00
- Resistance Level
- CRMD $11.41
- PCRX $18.34
- Average True Range (ATR)
- CRMD 0.73
- PCRX 0.84
- MACD
- CRMD -0.18
- PCRX -0.05
- Stochastic Oscillator
- CRMD 31.00
- PCRX 58.97
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.